This website uses cookies and similar technologies to provide the best functionality and display content according to your interests on our site and social networks.

We respect your privacy and process information only for marketing and functional purposes if you give us your consent by clicking ‘I accept.’
You can change your cookie settings at any time by clicking on the privacy settings.

Terms of use
Privacy Notice
Settings
This website uses cookies and similar technologies to provide the best functionality and display content according to your interests on our site and social networks.

We respect your privacy and process information only for marketing and functional purposes if you give us your consent by clicking ‘I accept.’
You can change your cookie settings at any time by clicking on the privacy settings.

Terms of use
Privacy Notice
This cookie is used for system purposes only and does not track user actions. It is required for normal functioning of this web site.
This is a web analytics service.
Processing company
  • Google Ireland Limited
  • Google Building Gordon House, 4 Barrow St, Dublin, D04 E5W5, Ireland
Data Purposes
  • Marketing
  • Advertisement
  • Web Analytics
Technologies Used
  • Cookies
  • Pixel Tags
Data Attributes
  • IP address (anonymised)
  • Browser information (browser type, referring/exit pages, the files viewed on our site, operating system, date/time stamp, and/or clickstream data)
  • Usage Data (views, clicks)
Data Collected
This list represents all (personal) data that is collected by or through the use of this service.
  • IP address
  • Date and time of visit
  • Usage data
  • Click path
  • App updates
  • Browser information
  • Device information
  • JavaScript support
  • Pages visited
  • Referrer URL
  • Downloads
  • Flash version
  • Location information
  • Purchase activity
  • Widget interactions
Legal Basis
  • In the following the legal basis for the processing of personal data required by Art. 6 I 1 GDPR is listed.
  • Art. 6 (1) (a) GDPR
Location of Processing
  • Republic of Serbia
Retention Period
  • The data will be deleted as soon as they are no longer needed for the processing purposes.
Data Recipients
  • Alphabet Inc.
This is a Tracking technology offered by Facebook and used by other Facebook services such as Facebook Custom Audiences.
Processing company
  • Facebook Ireland Limited
  • 4 Grand Canal Square, Grand Canal Harbour, Dublin, D02, Ireland
Data Purposes
  • advertising
  • Marketing
  • Retargeting
  • Analyse
  • Tracking
Technologies Used
  • Cookies
Data Attributes
  • Pixel specific data
  • Http-Header
  • Optional Parameters
Data Collected
This list represents all (personal) data that is collected by or through the use of this service.
  • Facebook user ID
  • Browser information
  • Usage data
  • Geräteinformationen
  • Non-sensitive custom data
  • Referrer URL
  • Pixel ID
  • Location information
  • Pixel specific data
  • User behaviour
  • Ads viewed
  • Interactions with advertisement, services, and products
  • Marketing information
  • Content viewed
  • IP address
Legal Basis
  • In the following the legal basis for the processing of personal data required by Art. 6 I 1 GDPR is listed.
  • Art. 6 para. 1 s. 1 lit. a GDPR
Location of Processing
  • Republic of Serbia
Retention Period
  • The data will be deleted as soon as they are no longer needed for the processing purposes.
Data Recipients
  • Facebook Inc.
Hemofarm – Reliable Partner of the Healthcare System of Serbia
29. March 2023.
The company Hemofarm, the leader in the pharmaceutical market of Serbia and the neighbouring region, marked the fifth anniversary of the innovative drug Corpos, intended for patients with multiple sclerosis. In the desire to provide the most contemporary therapy, Hemofarm has made the drug Corpos, which significantly changes the course of the disease and significantly improves the quality of life of people with multiple sclerosis, available to patients in Serbia.

On this occasion, the Prime Minister of the Government of the Republic of Serbia Ana Brnabić, the German Ambassador to Serbia Anke Konrad, the Minister of Science, Technological Development and Innovation Jelena Begović PhD, as well as numerous other representatives of state institutions visited Hemofarm.



The CEO of the company Hemofarm Ronald Seeliger, emphasized that the project Corpos was a good example of the public-private partnership and understanding of all parties about the important goal which is implemented in the interest of the community.

’This project is successful thanks to the partnership between the companies Hemofarm and Roche, the mutual trust we have built with the patient association and doctors, as well as the successful cooperation that Hemofarm has been achieving with state institutions for years,’ said Seeliger and added that Hemofarm will continue to be a reliable partner to the healthcare system of Serbia. He pointed out that since 2006, the STADA Group has invested over 400 million euros in Hemofarm, while investments worth over 30 million euros are planned for 2023 alone.



’Hemofarm is the leading pharmaceutical manufacturer in the region. At the same time, we are the largest exporter of medicines in Serbia and one of the most important pillars of production in the STADA Group. We will continue to strive to contribute to the sustainable development of the overall society through the improvement and development of Hemofarm,’ Seeliger concluded.

Ana Brnabić, Prime Minister of the Government of the Republic of Serbia, pointed out that the development of the domestic pharmaceutical industry is important for Serbia: ’Now that, thanks to all the expert people at Hemofarm, we have shown that we can produce the most complex innovative medicines, it is much easier to produce other innovative medicines as well in our country. I am proud and happy that Hemofarm is already talking with certain companies about the further production of innovative medicines in the Republic of Serbia. I want to thank Hemofarm, which employs more than 4,000 people in Serbia, because it is a pharmaceutical company that is the absolute largest exporter of medicines, but also the 13th largest exporter from the Republic of Serbia, ’ emphasized the Prime Minister of the Government of the Republic of Serbia, Ana Brnabić.



German Ambassador Anke Konrad spoke about the importance of the partnership between Germany and Serbia in all economic areas, especially in healthcare: ’I am glad to see that with Hemofarm, a German company is a key partner in the production of the drug Corpos. Hemofarm is not only the largest German investment in Serbia to date, but also an important employer for the region and an active promoter of the idea of sustainability.’

Hemofarm operates in 31 states on 3 continents. With more than 4,000 employees, Hemofarm is the pharmaceutical leader in Serbia in the fight for the people’s health.